Community Health Media

About Community Health Media

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Publisher

Community Health Media

Category

health & fitness

Language

en

Explicit

No

First episode

10 Jun 2025

Latest episode

20 Oct 2026

Latest episodes

78 episodes in the feed.

1. 

   20 Oct 2026

   HER2-Low & Ultralow Breast Cancer: Testing & T-DXd with Drs. Neil Iyengar & Sunil Badve

   Why does accurate HER2 testing matter more than ever for patients with breast cancer? Dr. Neil Iyengar and Dr. Sunil Badve discuss the evolving understanding of HER2-low and HER2-ultralow breast cancer and how advances in pathology and clinical evidence are expanding the population of patients who may be candidates for trastuzumab deruxtecan (T-DXd). Drawing on findings from DESTINY-Breast04 and DESTINY-Breast06, they explore how HER2 assessment has moved beyond the traditional amplified versus non-amplified framework, why accurately identifying low levels of HER2 expression matters, and how clinicians and pathologists can work together to reduce the risk of missing potential treatment opportunities. Topics discussed: How HER2 testing has evolved from identifying amplification to detecting low levels of protein expression Defining HER2-low, HER2-ultralow, and HER2-null disease Limitations of current HER2 assays at very low levels of expression Pre-analytic and analytic factors that can affect HER2 testing Key considerations when interpreting HER2 IHC results How DESTINY-Breast04 established T-DXd as a treatment option in HER2-low metastatic breast cancer How DESTINY-Breast06 expanded the discussion to HER2-ultralow disease and earlier use of T-DXd Why repeat biopsy and reassessment of HER2 expression can matter When archival tissue or a pathology second opinion may be useful Tumor heterogeneity and changes in HER2 expression over time and across metastatic sites HER2-low expression in hormone receptor-positive and triple-negative breast cancer Managing T-DXd-associated nausea, fatigue, ILD, and cardiac considerations Improving concordance in HER2 assessment through training and standardized testing The emerging role of AI and quantitative tools in evaluating HER2 expression What DESTINY-Breast15 could mean for HER2 testing and patients with HER2 IHC 0 disease ▶️ Watch the full CHM Conversation for expert perspectives on HER2 testing, evolving pathology standards, and identifying patients who may benefit from T-DXd. #NeilIyengar #SunilBadve #CHMConversations #HER2Low #HER2Ultralow #BreastCancer #TDXd #TrastuzumabDeruxtecan #DESTINYBreast04 #DESTINYBreast06 #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: Spotify - https://spotf.fi/chm-podcast (https://spotf.fi/chm-podcast) Amazon Music - https://amazn.so/chm-podcast (https://amazn.so/chm-podcast) Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 (https://podcasts.apple.com/us/podcast/community-health-media/id1837428248) Castbox - https://castbox.fm/vh/6735434 (https://castbox.fm/vh/6735434) Goodpods - https://goodpods.com/profile/chm-111066 (https://goodpods.com/profile/chm-111066) iHeartRadio - https://iheart.com/podcast/291542082 (https://iheart.com/podcast/291542082) Pocket Casts - https://pca.st/3ncdh11o (https://pca.st/3ncdh11o) – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: Peer to peer interviews, panels & round-tables Curated live events & conferences Professional in-depth content & research updates Interactive learning modules & webinars Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media (https://communityhealth.media)

2. 

   7 Oct 2026

   Special CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino

   How is the rapidly changing treatment landscape reshaping second-line ER-positive, HER2-negative metastatic breast cancer care? In this Special CHM Conversation, Dr. Seth Wander and Dr. Paolo Tarantino discuss the growing number of endocrine therapy options and how clinicians can navigate increasingly complex treatment decisions. They explore what the newly approved combination of imlunestrant plus abemaciclib means for patients with ESR1 mutations, how ctDNA and molecular profiling guide treatment selection, and why sequencing next-generation endocrine therapies remains an open question as new options emerge. Topics discussed: EMBER-3 and imlunestrant plus abemaciclib Treatment options for ESR1-mutated disease Single-agent vs combination endocrine therapy ctDNA and molecular profiling Biomarker-driven treatment selection Balancing efficacy and tolerability SERENA-6 and molecular progression Sequencing next-generation endocrine therapies Oral SERDs in the adjuvant and first-line settings Emerging doublet and triplet strategies ▶️ Watch this Special CHM Conversation for expert perspectives on navigating the evolving second-line treatment landscape in ER-positive, HER2-negative metastatic breast cancer. #SethWander #PaoloTarantino #CHMConversations #ESR1 #EMBER3 #EndocrineTherapy #OralSERD #MetastaticBreastCancer #BreastCancer #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast (https://spotf.fi/chm-podcast) • Amazon Music - https://amazn.so/chm-podcast (https://amazn.so/chm-podcast) • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 (https://podcasts.apple.com/us/podcast/community-health-media/id1837428248) • Castbox - https://castbox.fm/vh/6735434 (https://castbox.fm/vh/6735434) • Goodpods - https://goodpods.com/profile/chm-111066 (https://goodpods.com/profile/chm-111066) • iHeartRadio - https://iheart.com/podcast/291542082 (https://iheart.com/podcast/291542082) • Pocket Casts - https://pca.st/3ncdh11o (https://pca.st/3ncdh11o) – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: Peer to peer interviews, panels & round-tables Curated live events & conferences Professional in-depth content & research updates Interactive learning modules & webinars Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media (https://communityhealth.media)

3. 

   6 Oct 2026

   ESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton

   How should clinicians navigate the growing number of treatment options for ESR1-mutated metastatic breast cancer? Dr. Jason Mouabbi and Dr. Erika Hamilton discuss the evolving treatment landscape for hormone receptor-positive, HER2-negative metastatic breast cancer, with a focus on ESR1 mutations, molecular testing, PROTACs, oral SERDs, and treatment sequencing. They explore when and how to test for ESR1 mutations, including the role of liquid biopsy and serial testing as resistance emerges. The conversation also examines the differences between a PROTAC and oral SERDs, the clinical data supporting vepdegestrant, and how emerging combination strategies could further reshape endocrine therapy. Topics discussed: • Why ESR1 mutations matter in HR-positive/HER2-negative metastatic breast cancer • When to test and retest for ESR1 mutations • Tissue NGS vs liquid biopsy for detecting ESR1 mutations • ESR1 as both a resistance mechanism and a predictive biomarker • Current treatment options for ESR1-mutated disease • How PROTACs differ from oral SERDs • VERITAC-2 and the clinical data supporting vepdegestrant • Understanding VERITAC-2, EMERALD, and EMBER-3 • Tolerability, GI toxicity, fatigue, and QTc monitoring with vepdegestrant • Selecting among endocrine monotherapy options • Retesting ESR1 after progression on an oral SERD • Sequencing a PROTAC after prior oral SERD therapy • Imlunestrant plus abemaciclib and emerging combination strategies • SERENA-6 and switching therapy at molecular progression • Molecular progression vs radiologic progression • The future role of PROTAC and CDK4/6 inhibitor combinations • Why endocrine monotherapy still has an important role • Preserving endocrine therapy before transitioning to antibody-drug conjugates • Reconsidering endocrine therapy after treatment with an ADC • The growing importance of genomic profiling and personalized treatment sequencing ▶️ Watch the full CHM Conversation for expert perspectives on ESR1 testing, endocrine resistance, treatment selection, and the evolving role of oral SERDs and PROTACs in metastatic breast cancer. #JasonMouabbi #ErikaHamilton #CHMConversations #BreastCancer #MetastaticBreastCancer #ESR1 #HRPositiveBreastCancer #HER2Negative #Vepdegestrant #OralSERD #PROTAC #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Who has been a guest on Community Health Media

Names identified in recent episode analyses. Showing up to five guests.

• Sonya Reid
• Shruti Singh
• Senthil Damodaran
• Mothaffar Rimawi
• Michelina Cairo

Contact Community Health Media

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.